Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem cell transplantation i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Carmustine (carmustine)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Venetoclax (venetoclax)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-14